- Home
- SYTA vs ATXI Comparison
SYTA vs ATXI Comparison
Compare SYTA & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- ATXI
- Stock Information
- Founded
- SYTA N/A
- ATXI 2015
- Country
- SYTA Canada
- ATXI United States
- Employees
- SYTA N/A
- ATXI N/A
- Industry
- SYTA Telecommunications Equipment
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- ATXI Health Care
- Exchange
- SYTA Nasdaq
- ATXI Nasdaq
- Market Cap
- SYTA 2.9M
- ATXI 3.0M
- IPO Year
- SYTA 2020
- ATXI 2017
- Fundamental
- Price
- SYTA $1.27
- ATXI $1.93
- Analyst Decision
- SYTA
- ATXI Strong Buy
- Analyst Count
- SYTA 0
- ATXI 1
- Target Price
- SYTA N/A
- ATXI $56.25
- AVG Volume (30 Days)
- SYTA 7.4M
- ATXI 78.9K
- Earning Date
- SYTA 11-14-2024
- ATXI 11-14-2024
- Dividend Yield
- SYTA N/A
- ATXI N/A
- EPS Growth
- SYTA N/A
- ATXI N/A
- EPS
- SYTA N/A
- ATXI N/A
- Revenue
- SYTA $11,988,979.00
- ATXI N/A
- Revenue This Year
- SYTA $78.40
- ATXI N/A
- Revenue Next Year
- SYTA $18.06
- ATXI N/A
- P/E Ratio
- SYTA N/A
- ATXI N/A
- Revenue Growth
- SYTA 41.59
- ATXI N/A
- 52 Week Low
- SYTA $0.76
- ATXI $1.60
- 52 Week High
- SYTA $90.90
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- SYTA 51.67
- ATXI 38.77
- Support Level
- SYTA $1.17
- ATXI $1.97
- Resistance Level
- SYTA $1.29
- ATXI $2.41
- Average True Range (ATR)
- SYTA 0.14
- ATXI 0.19
- MACD
- SYTA 0.02
- ATXI -0.03
- Stochastic Oscillator
- SYTA 44.19
- ATXI 34.02
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.